MAPK3 and acute lymphoblastic leukemia: Inhibition of MERTK in B-ALL prevented ERK1/2 activation, increased the sensitivity of B-ALL cells to cytotoxic agents, promoted apoptosis, and delayed disease onset in a mouse model of leukemia.